The German-Israeli Cooperation in Cancer Research was founded in 1976 and belongs to the longest lasting scientific cooperations of both countries. To date, more than 160 joint projects have been funded. Importantly, the cooperation has also strongly fostered friendship between scientists from Germany and Israel and other involved partners (www.dkfz.de/israel).

The aim of the German-Israeli Cancer Research School established in 2008 is to provide a platform for intensive interaction between students, young researchers and principal investigators from both nationalities on essential and emerging areas of cancer research.

The 8th German-Israeli Cancer Research School in November 2016 is dedicated to Cancer Immunotherapy. On this occasion, we will review the spectacular recent progress in this area with respect to the clinical application of – for instance – checkpoint inhibitors and adoptive T cell therapies, discuss the latest insights in the regulation of immunity in health and disease, and – most importantly – aim at identifying new opportunities in the pre-clinical and clinical tumor immunology research.

The meeting offers an exciting program of seminars by 16 cancer immunotherapy/tumor immunology experts, 8 from Israel and 8 from Germany. This year’s keynote lecture will be delivered by Prof. Zelig Eshhar, who has recently received the Israel Prize for his contributions to the field.

An important aspect of this year’s program is that all participating PhD students will present their own project at prime time during the meeting. On each morning between 10.30 and noon, 8 PhD students will give 10-minute flash-talks, after which they can display their work in further details during the subsequent poster session. The best posters will be awarded.

Since we will be staying close to Jerusalem, we will – of course – have an excursion to this famous historic city. Last but not least, we will have a special lecture by Prof. Amotz Zahavi, a famous Israeli evolutionary biologist who brought forward the ‘Handicap Principle’, an intensely debated theory aimed at explaining why animals – and humans – invest so much energy in physical and behavioral displays.

Peter Angel  Hagit Schwimmer

INVITATION

The German-Israeli Cooperation in Cancer Research was founded in 1976 and belongs to the longest lasting scientific cooperations of both countries. To date, more than 160 joint projects have been funded. Importantly, the cooperation has also strongly fostered friendship between scientists from Germany and Israel and other involved partners (www.dkfz.de/israel).

The aim of the German-Israeli Cancer Research School established in 2008 is to provide a platform for intensive interaction between students, young researchers and principal investigators from both nationalities on essential and emerging areas of cancer research.

The 8th German-Israeli Cancer Research School in November 2016 is dedicated to Cancer Immunotherapy. On this occasion, we will review the spectacular recent progress in this area with respect to the clinical application of – for instance – checkpoint inhibitors and adoptive T cell therapies, discuss the latest insights in the regulation of immunity in health and disease, and – most importantly – aim at identifying new opportunities in the pre-clinical and clinical tumor immunology research.

The meeting offers an exciting program of seminars by 16 cancer immunotherapy/tumor immunology experts, 8 from Israel and 8 from Germany. This year’s keynote lecture will be delivered by Prof. Zelig Eshhar, who has recently received the Israel Prize for his contributions to the field.

An important aspect of this year’s program is that all participating PhD students will present their own project at prime time during the meeting. On each morning between 10.30 and noon, 8 PhD students will give 10-minute flash-talks, after which they can display their work in further details during the subsequent poster session. The best posters will be awarded.

Since we will be staying close to Jerusalem, we will – of course – have an excursion to this famous historic city. Last but not least, we will have a special lecture by Prof. Amotz Zahavi, a famous Israeli evolutionary biologist who brought forward the ‘Handicap Principle’, an intensely debated theory aimed at explaining why animals – and humans – invest so much energy in physical and behavioral displays.

Peter Angel  Hagit Schwimmer

ORGANIZERS

Scientific Program Committee
DKFZ: Prof. Dr. Rienk Offringa
Israel: Prof. Dr. Roni Apte and Prof. Dr. Varda Rotter

German-Israeli Cooperation in Cancer Research
DKFZ: Prof. Dr. Peter Angel
Israel: Dr. Hagit Schwimmer

Administrative Coordinator
Susanne Schunk

Contact Address DKFZ
Susanne Schunk
German Cancer Research Center (DKFZ)
Im Neuenheimer Feld 280
D-69120 Heidelberg, Germany
phone: +49 6221 42-4499
e-mail: susanne.schunk@dkfz.de

Contact Address MOST
Shani Edri / Aviel Abraham
Ministry of Science, Technology and Space
P. O. Box 49100
Jerusalem 91490, Israel
phone: +972 2 5411850
e-mail: shanie@most.gov.il / avielab@most.gov.il

Venue
Location near Jerusalem, Israel (TBD)

Participation
Participation is restricted to 24 students and junior postdocs (12 from DKFZ and 12 from Israel) who will be selected on basis of CV and abstract by the Joint Scientific Committee.

Application
For application see www.dkfz.de/en/israel/school-2016/school-2016.html. Please, send application form together with poster abstract to DKFZ-School@most.gov.il by August 5th, 2016. There will be no registration fee; accommodation, breakfast and dinner are covered by the organizers.
Sunday, November 20th, 2016

Arrival in the afternoon
19:00 Welcome Dinner

Monday, November 21th, 2016

08:30 Ofer Mandelboim
Recognition of bacteria by NK cells
09:15 Angel Porgador
Natural killer immunity and cancer immu-
nome
10:00 Break
10:30 Flash talks by PhD students and junior postdocs
12:00 PhD students and junior postdocs poster
session and lunch buffet
13:30 Thomas Woelfel
Analyses of the anti-tumor T cell repertoire
in melanoma patients
14:15 Gerald Willimsky
Identification of tumor-specific rejection
antigens for TCR gene therapy
15:00 Michael Platten
Immunotherapy of brain tumors
15:45 Break
16:15 Barbara Seliger
Many mechanisms of tumors leading to
target-less T cells
17:00 Gal Markel
Immune resistance mechanisms in melanoma
17:45 Happy hour
19:00 Dinner, followed by a social activity

Tuesday, November 22th, 2016

08:30 Ron Apte
Microenvironment IL-1 is a major determinator
of the balance between immunity and inflam-
mation at tumor sites
09:15 Vigo Heissmeyer
Roquin-deficient T cells create a tumor-induc-
ing micro-milieu in the pancreas
10:00 Break
10:30 Flash talks by PhD students and junior postdocs
12:00 PhD students and junior postdocs poster
session and lunch buffet
13:30 Afternoon excursion to Jerusalem
19:00 Dinner

Wednesday, November 23th, 2016

10:30 Flash talks by PhD students and junior post-
docs
12:00 PhD students and junior postdocs poster
session and lunch buffet
13:30 KEYNOTE LECTURE:
Zelig Eshhar
The chimeric antigen receptor T cells: from
the mouse Cage to the patient health
14:15 Yoram Reitter
Engineering immune molecules and cells for
novel cancer immunotherapy
15:00 Michael Bachmann
Retargeting of immune cells to tumor cells
15:45 Break
16:15 Jacob Schachter
Immunotherapy – the new platform for the
treatment of cancer
17:00 Rienk Offringa
Immunotherapy of pancreatic cancer in the
neo-adjuvant and adjuvant setting
17:45 Happy hour
19:00 Closing dinner party